Related references
Note: Only part of the references are listed.US Renal Data System 2017 Annual Data Report Epidemiology of Kidney Disease in the United States
Rajiv Saran et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
ISPD PERITONITIS RECOMMENDATIONS: 2016 UPDATE ON PREVENTION AND TREATMENT
Philip Kam-Tao Li et al.
PERITONEAL DIALYSIS INTERNATIONAL (2016)
Ertapenem Pharmacokinetics and Pharmacodynamics during Continuous Ambulatory Peritoneal Dialysis
Katie E. Cardone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function
Sunil V. Badve et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Pharmacokinetics and Pharmacodynamics of Intravenous Daptomycin during Continuous Ambulatory Peritoneal Dialysis
Katie E. Cardone et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study
Dwarakanathan Ranganathan et al.
BMC NEPHROLOGY (2009)
Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving Hemodialysis
Lily Dang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: Effect on residual renal function
SL Lui et al.
KIDNEY INTERNATIONAL (2005)
Pharmacodynamics and dosing of aminoglycosides
J Turnidge
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2003)
Empirical aminoglycosides for peritonitis do not affect residual renal function
RJ Baker et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2003)
Share Paper
